RECENT DEVELOPMENTS IN ANTIBIOTIC THERAPY
Authors: L A RANTZ
Journal: Annals of Internal Medicine (1960)

Article1 February 1960RECENT DEVELOPMENTS IN ANTIBIOTIC THERAPYLOWELL A. RANTZ, M.D., F.A.C.P.LOWELL A. RANTZ, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-2-362 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe most interesting developments in the field of antimicrobial therapy have centered about the introduction of a number of new agents. Some of these are modifications of, or are closely related to, drugs already in use, whereas others are completely new.Sulfonamides:Two sulfonamide drugs, sulfamethoxypyridazine (Kynex)1and sulfadimethoxine (Madribon),2, 3have recently received wide clinical trial. Both have similar properties in that they are absorbed rapidly and well from the gastrointestinal tract and excreted slowly by the kidney. Treatment is thus possible with a single daily dose of 0.5 to 1.0 gm., and renal complications due to a high...Bibliography1. JonesFinland WFM: Sulfamethoxypyridazine and sulfachlorpyridazine, Ann. New York Acad. Sc. 69: 473, 1957. CrossrefMedlineGoogle Scholar2. RossPuigZaremba SJREA: Sulfadimethoxine, a new long-acting sulfonamide. Some preliminary clinical and laboratory observations in infants and children, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 56-63. Google Scholar3. Boger WP: A new long-acting antibacterial sulfonamide, 2,4-dimethoxy-6-sulfanilamido-1, 3-diazine: a comparative study, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 48-55. Google Scholar4. LepperSimonMarienfeld MHAJCJ: Use of sulfamethoxypyridazine in the prevention of streptococcal infections in rheumatic patients, Ann. New York Acad. Sc. 69: 485-492, 1957. CrossrefMedlineGoogle Scholar5. Finland M: Antibiotic blood level enhancement, Antibiotic Med. and Clin. Therap. 5: 359-363, 1958. MedlineGoogle Scholar6. KuninJonesFinland CMWFM: Enhancement of tetracycline blood levels, New England J. Med. 259: 147-156, 1958. CrossrefMedlineGoogle Scholar7. KuninFinland CMM: Dimethylchlortetracycline. A new tetracycline antibiotic that yields greater and more sustained antibacterial activity, New England J. Med. 259: 999-1005, 1958. CrossrefMedlineGoogle Scholar8. RantzRandallThumBarker LAELLF: The effects of vancomycin, oleandomycin, and novobiocin on staphylococci in vitro , Antibiotics and Chemotherapy 7: 399-409, 1957. Google Scholar9. KuninPrylesFinland CMCVM: Antibacterial activity of serum after oral doses of triacetyloleandomycin, erythromycin, potassium penicillin V and penicillin V, Pediatrics 22: 422-431, 1958. MedlineGoogle Scholar10. HirschKuninFinland HACMM: Antibacterial activity of serum of normal men after oral doses of erythromycin propionate and triacetyloleandomycin, New England J. Med. 260: 408-412, 1959. CrossrefMedlineGoogle Scholar11. Waksman SA, Editor: Neomycin, 1958, The Williams and Wilkins Company, Baltimore. Google Scholar12. KuninWilcoxNajarianFinland CMCAM: Susceptibility and cross-resistance of bacteria to four related antibiotics: kanamycin, paromomycin, neomycin and streptomycin, Proc. Soc. Exper. Biol. and Med. 99: 312-316, 1958. CrossrefMedlineGoogle Scholar13. Finland M: Kanamycin, Lancet 2: 209-211 (July 26) 1958. CrossrefMedlineGoogle Scholar14. FrostDalyHawkins JOJFJE: The ototoxicity of kanamycin in man, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 700-707. Google Scholar15. FinegoldWinfieldNishizawaKantorKvingeHewitt SMMEAEAVEWL: Clinical evaluation of kanamycin, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 606-622. Google Scholar16. Jawetz E: Combined antibiotic therapy in serious infections caused by drug resistant staphylococci, Arch. Int. Med. 103: 289, 1959. CrossrefGoogle Scholar17. KirbyPerryLane WMDMJL: Present status of vancomycin therapy of staphylococcal and streptococcal infections, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 580-586. Google Scholar18. Bush LF: Use of ristocetin (Spontin) in staphylococcal infections, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 454-457. Google Scholar19. TerryBradley RBLF: Ristocetin in adults and children, in Antibiotics annual 1958-1959, Medical Encyclopedia, Inc., New York, 1959, pp. 458-463. Google Scholar20. CalvySchumacher GLLR: Ristocetin and the staphylococcus. Observations of effects and side-effects in seventeen cases of staphylococcic pneumonia, J. A. M. A. 167: 1584-1586 (July 26) 1958. CrossrefMedlineGoogle Scholar21. NewtonWard RMVG: Leukopenia associated with ristocetin (Spontin) administration. Report of two cases, J. A. M. A. 166: 1956-1959 (Apr. 19) 1958. CrossrefMedlineGoogle Scholar22. RantzJawetz LAE: Failure of ristocetin therapy in three cases of staphylococcal sepsis with bacteremia, New England J. Med. 259: 963, 1958. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Palo Alto, California*Received for publication May 16, 1959.Presented at the Fortieth Annual Session of The American College of Physicians, Chicago, Illinois, April 23, 1959.From the Department of Medicine, Stanford University School of Medicine, San Francisco, California.Requests for reprints should be addressed to Lowell A. Rantz, M.D., Professor of Medicine, Stanford Medical Center, 300 Pasteur Drive, Palo Alto, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntimicrobial Therapy in Heart Disease in Children 1 February 1960Volume 52, Issue 2Page: 362-367KeywordsAntibioticsAntimicrobialsClinical trialsDrugsGastrointestinal tractKidneysStaphylococcal infectionSulfonamide ePublished: 1 December 2008 Issue Published: 1 February 1960 PDF downloadLoading ...